Prelude Therap Rg

Clinical‑stage precision oncology firm focused on SMARCA2 degraders and CDK9 inhibitors for advanced solid tumors, offering Phase 1 pipeline including PRT3789, PRT7732, and PRT2527. Headquartered in Wilmington, Delaware.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 131
HQ: Wilmington

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
PRLD	Prelude Therap Rg Cap: 0.2B	EQUITY	NMS	USD	US74065P1012	Active	📈